Investment in antimalarial drug development is bearing fruit
-
Published:2017-06
Issue:6
Volume:17
Page:568-570
-
ISSN:1473-3099
-
Container-title:The Lancet Infectious Diseases
-
language:en
-
Short-container-title:The Lancet Infectious Diseases
Subject
Infectious Diseases
Reference7 articles.
1. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study;Amaratunga;Lancet Infect Dis,2016
2. Declining efficacy of artemisinin combination therapy against P falciparum malaria on the Thai–Myanmar Border (2003–2013): the role of parasite genetic factors;Phyo;Clin Infect Dis,2016
3. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam;Thanh;Malaria J,2017
4. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study;McCarthy;Lancet Infect Dis,2017
5. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection;Sulyok;Lancet Infect Dis,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献